{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:13:16Z","timestamp":1777489996480,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Following the CENTURION phase 3 randomized controlled trial\u2019s four-month double-blind phase, this 12-month open-label extension collected data for up to one year about dose optimization, patterns of use, migraine-related disability, and quality of life during lasmiditan treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Migraine patients \u226518 years completing the double-blind phase and treating \u22653 migraine attacks could continue into the 12-month open-label extension. The initial oral lasmiditan dose was 100\u2009mg; the dose could subsequently be adjusted to 50\u2009mg or 200\u2009mg at the investigator\u2019s discretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>477 patients entered and 321 (72.1%) completed the extension; 445 (93.3%) treated \u22651 attack with lasmiditan. Of 11,327 attacks, 8654 (76.4%) were lasmiditan-treated (84.9% of these involved moderate or severe pain). By study end, 17.8%, 58.7%, and 23.4% of patients were taking lasmiditan 50, 100, and 200\u2009mg, respectively. Mean improvements were observed in disability and quality of life. The most common treatment-emergent adverse event was dizziness (35.7% of patients, 9.5% of attacks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During this 12-month extension, lasmiditan was associated with a high rate of study completion, most attacks were treated with lasmiditan, and patients reported improvements in migraine-related disability and quality of life. No new safety findings were observed with longer exposure. Trial registration: ClinicalTrials.gov (NCT03670810); European Union Drug Regulating Authorities Clinical Trials Database (EUDRA CT: 2018-001661-17).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024231161745","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:08:59Z","timestamp":1679544539000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial"],"prefix":"10.1177","volume":"43","author":[{"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[{"name":"Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Roos","sequence":"additional","affiliation":[{"name":"H\u00f4pital Lariboisi\u00e8re, Assistance Publique \u2013 H\u00f4pitaux de Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ayer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Ruff","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Henry","family":"Krege","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"bibr1-03331024231161745","unstructured":"Eli Lilly and Company. Full Prescribing Information: REYVOW\u00ae (lasmiditan) tablets, for oral use (package insert). Indianapolis, Indiana, USA: Eli Lilly and Company, 2021."},{"key":"bibr2-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"bibr3-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"bibr4-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989232"},{"key":"bibr5-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01088-4"},{"key":"bibr6-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"bibr7-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1111\/head.13657"},{"key":"bibr8-03331024231161745","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1903846"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231161745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024231161745","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231161745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:42Z","timestamp":1777387542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024231161745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/03331024231161745"],"URL":"https:\/\/doi.org\/10.1177\/03331024231161745","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"03331024231161745"}}